Johnson & Johnson COVID-19 vaccine candidate moves forward to phase 3

by on

Johnson & Johnson COVID-19 vaccine candidate moves forward to phase 3
tjordan_drupal
Sep 23, 2020

Johnson & Johnson today said  that its COVID-19 vaccine candidate is moving to a global phase 3 clinical trial.

The JNJ-78436735 vaccine candidate, which was developed by J&J subsidiary Janssen Pharmaceutical Companies, will be administered to 60,000 volunteers at 215 clinical sites across three continents. The vaccine is believed to be the first COVID-19 candidate that would require just a single dose to spur immunity in patients.

The trial will be funded by Johnson & Johnson/Janssen, the National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority.

Headline

Johnson & Johnson COVID-19 vaccine candidate moves forward to phase 3
tjordan_drupal
Sep 23, 2020

Johnson & Johnson today said  that its COVID-19 vaccine candidate is moving to a global phase 3 clinical trial.

The JNJ-78436735 vaccine candidate, which was developed by J&J subsidiary Janssen Pharmaceutical Companies, will be administered to 60,000 volunteers at 215 clinical sites across three continents. The vaccine is believed to be the first COVID-19 candidate that would require just a single dose to spur immunity in patients.

The trial will be funded by Johnson & Johnson/Janssen, the National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority.

COVID-19: Vaccine
Novel Coronavirus (COVID-19)

Headline

VA:F [1.9.7_1111]
Rating: 0.0/10 (0 votes cast)
VA:F [1.9.7_1111]
Rating: 0 (from 0 votes)

Leave a Comment

Previous post:

Next post: